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doi:10.1
824Objective: The effects of ventricular restraint level on left ventricular reverse remodeling are not known. We
hypothesized that restraint level affects the degree of reverse remodeling and that restraint applied in an adjust-
able manner is superior to standard, nonadjustable restraint.
Methods: This study was performed in 2 parts using a model of chronic heart failure in the sheep. In part I, re-
straint was applied at control (0 mmHg, n¼ 3), low (1.5 mmHg, n¼ 3), and high (3.0 mmHg, n¼ 3) levels with
an adjustable and measurable ventricular restraint (AMVR) device. Restraint level was not altered throughout
the 2-month treatment period. Serial restraint level measurements and transthoracic echocardiography were per-
formed. In part II, restraint was applied with the AMVR device set at 3.0 mm Hg (n ¼ 6) and adjusted period-
ically to maintain that level. This was compared with restraint applied in a standard, nonadjustable manner using
a mesh wrap (n ¼ 6). All subjects were followed up for 2 months with serial magnetic resonance imaging.
Results: In part I, there was greater and earlier reverse remodeling in the high restraint group. In both groups, the
rate of reverse remodeling peaked and then declined as the measured restraint level decreased with progression
of reverse remodeling. In part II, adjustable restraint resulted in greater reverse remodeling than standard re-
straint. Left ventricular end diastolic volume decreased by 12.7% (P ¼ .005) with adjustable restraint and by
5.7% (P ¼ .032) with standard restraint. Left ventricular ejection fraction increased by 18.9% (P ¼ .014)
and 14.4% (P<.001) with adjustable and standard restraint, respectively.
Conclusions:Restraint level affects the rate and degree of reverse remodeling and is an important determinant of
therapy efficacy. Adjustable restraint is more effective than nonadjustable restraint in promoting reverse remod-
eling. (J Thorac Cardiovasc Surg 2013;145:824-31)Ventricular restraint therapy is a nontransplant surgical
treatment for heart failure in which both ventricles are
wrapped with prosthetic material.1,2 The intent is to
mechanically constrain the ventricles without causing
excessive diastolic constriction or tamponade. Numerous
studies have demonstrated that restraint not only prevents
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The Journal of Thoracic and Cardiovascular Surginduces reverse remodeling at both the molecular and
systemic levels.3-6
Restraint devices tested in clinical trials, however, do not
allow for either the measurement or adjustment of wrap
tightness; the restraint level is not quantified. Such restraint
devices are applied around the heart at a subjective level of
tightness. The influence of restraint level on therapy effi-
cacy is thus unclear. To address this issue, we developed
and described a new technique—adjustable and measurable
ventricular restraint (AMVR)—in which a fluid-filled epi-
cardial balloon is placed around the heart.7 By use of a fluid
layer to effect restraint, adjustability and measurability of
therapy was achieved.
We demonstrated with AMVR that restraint decreases LV
transmural myocardial pressure and indices of myocardial
oxygen consumption in a restraint level–dependent man-
ner.7 Progressively higher levels of restraint will ultimately
cause tamponade, however, and we showed that this tampo-
nade physiology is secondary to (RV) constriction only.8
When restraint is applied in a fixed, constant manner, our re-
sults demonstrate that the rate of reverse remodeling slows
as the heart shrinks and undergoes reverse remodeling.
These findings suggest that the interplay between restraintery c March 2013
Abbreviations and Acronyms
AMVR ¼ adjustable and measurable ventricular
restraint
BNP ¼ brain natriuretic peptide
CMR ¼ cardiac magnetic resonance
EDV ¼ end-diastolic volume
EF ¼ ejection fraction
ESV ¼ end-systolic volume
LV ¼ left ventricular
MMP-2 ¼ myocardial matrix metalloproteinase-2
RV ¼ right ventricular
Lee et al Evolving Technology/Basic Sciencetherapy and ventricular remodeling is a dynamic process
that may require periodic adjustment of restraint level to
maintain therapeutic efficacy.
In this study, we seek to definitively investigate the role
that restraint level plays in inducing reverse remodeling. Al-
though our previous studies delineated the relationship be-
tween restraint level and acute ventricular mechanical
indices, these were not long-term in vivo studies evaluating
the relationship between restraint level and reverse remod-
eling itself. For the present study, we hypothesized that (1)
the initial, or starting, restraint level is a key determinant of
the degree of reverse remodeling in standard, nonadjusted
restraint therapy and (2) restraint therapy applied in an op-
timized, adjustable manner is superior to restraint applied in
a fixed, nonadjustable manner in promoting reverse
remodeling.E
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Study Design Overview
This study was performed in 2 parts: (1) a 4-month study investigating
the effects of different initial restraint levels on reverse remodeling and (2)
a 4-month study comparing optimized, adjustable restraint therapy to stan-
dard, nonadjustable restraint therapy.
In part I, 9 sheep underwent coronary artery ligation through a left tho-
racotomy to develop heart failure. Animals were then divided into 3 equal
groups: control (no restraint), low restraint (1.5 mm Hg), and high restraint
(3.0 mm Hg). Nine total sheep were used. The control group had no re-
straint device implanted. Low and high restraint groups underwent reoper-
ative median sternotomy with implantation of the AMVR device. The
restraint device was filled with fluid to achieve the desired restraint levels
(1.5 mm Hg in the low group and 3.0 mm Hg in the high group). Restraint
level was defined by the measured balloon luminal pressure at end-diastole.
The levels chosen were based on our previous results with this animal
model demonstrating beneficial changes at these restraint levels. Restraint
levels greater than 3.0 mm Hg were not tested because our previous results
demonstrated decreased cardiac output with impaired RV filling at those
higher levels, suggesting that 3.0 mm Hg is the optimal restraint level for
this particular model.7,8
After device placement, all subjects were followed up for 2 months with
serial transthoracic echocardiography. The volume of fluid in the AMVR
device was not altered to reflect the unchanging nature of clinical devices.
Restraint level was measured weekly throughout the study period to assess
the effect of reverse remodeling on restraint level. A terminal experiment
was performed to obtain and analyze myocardial tissue samples forThe Journal of Thoracic and Camolecular markers of remodeling. The long-term effects of the initial start-
ing restraint level on ventricular volumes and the level of restraint itself
were then measured and compared.
In part II, 12 sheep underwent coronary artery ligation, and heart failure
developed by 2 months postoperatively in all of them. Animals were then
divided into 2 groups: standard, nonadjustable restraint (n ¼ 6) and opti-
mized, adjustable restraint (n ¼ 6). All sheep underwent reoperative me-
dian sternotomy for implantation of the assigned treatment device. In the
standard restraint group, a polypropylene mesh was wrapped around the
heart to simulate unchanging restraint devices. In the adjustable restraint
group, AMVR devices were implanted and set at a restraint level of 3.0
mm Hg. This level was chosen because our previously published studies
showed this to be the optimal restraint level at which beneficial changes
in ventricular mechanical indices are maximized while adverse systemic
hemodynamic effects are minimized in this particular sheep model.7,8
All 12 subjects were then followed up for 2 months with serial cardiac
magnetic resonance (CMR) imaging. In the adjustable restraint group, the
restraint level was measured biweekly and the volume in the restraint de-
vice adjusted to maintain a restraint pressure of 3.0 mm Hg throughout
the study duration. No postoperative measurement or manipulation of re-
straint level was possible in the fixed restraint group simulating standard
clinical restraint. Blood samples were obtained biweekly in all animals
to assess for plasma markers of remodeling. A terminal experiment was
performed to obtain and analyze myocardial tissue samples for molecular
markers of remodeling.
A total of 21 (9 in part I, 12 in part II) adult male sheep (30-40 kg) were
used for the 2 parts of this study. All animals received humane care in com-
pliance with the ‘‘Guide for Care and Use of Laboratory Animals’’ pub-
lished by the National Institutes of Health (NIH publication no. 86-23,
revised 1996). The protocol was approved by the Institutional Animal
Care and Use Committee of Harvard Medical School.
The specific techniques and methodologies used are described below.
Heart failure model. An ovine model of postinfarction heart failure
involving ligation of the first and second diagonal coronary arteries was
used.7-9 Heart failure, defined as an LV ejection fraction (EF) less than
40% and a 100% increase in LVend-diastolic volume (EDV) from preop-
erative baseline, was confirmed by either echocardiography or CMR
imaging.
Adjustable and measurable ventricular restraint. The
AMVR device is a half-ellipsoidal balloon constructed from medical-
grade polyurethane sheets (Polyzen, Inc, Apex, NC) and has been de-
scribed previously.7 Each balloon is composed of 2 layers. An access
line placed between the 2 layers allows for pressure measurement inside
the balloon lumen and the addition or withdrawal of fluid. Because the
outer layer of the balloon is relatively nonstretchable, fluid introduced
into the balloon lumen has only 1 direction of filling space—inward toward
the heart, thereby creating a tighter wrap. Conversely, withdrawal of fluid
from the balloon lumen creates a looser wrap. The device is placed around
the heart via median sternotomy and sutured to the atrioventricular groove
such that both ventricles are covered. The balloon access line is connected
to an implantable catheter (Port-a-Cath; Bard Medical, Covington, Ga),
which is placed in the chest wall. The port can be accessed with an 18-
gaugeHuber needle and connected to a Statham P10EZ pressure transducer
(SpectraMed, Oxford, Calif). Measuring the pressure within the balloon
when the heart is largest in size—end-diastole—allows wrap tightness
(or restraint level) to be precisely quantified. Restraint level is changed
by adding or removing fluid from the balloon while luminal pressure is
monitored in real time.
Standard, nonadjustable ventricular restraint. Standard,
fixed restraint intended to simulate clinically tested restraint devices was
achieved with a polypropylene mesh wrap (Ethicon, Inc, Somerville,
NJ). A median sternotomy was performed and the mesh was placed around
the heart in accordance with guidelines used for placement of the Acorn
CorCap cardiac support device (Acorn Cardiovascular, Inc, St Paul,rdiovascular Surgery c Volume 145, Number 3 825
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tricular groove such that LV EDV decreased by 5% on intraoperative epi-
cardial echocardiography.10,11 No measurement or adjustment of restraint
level was possible in the postoperative period.
Transthoracic echocardiography. In part I, quantitative
2-dimensional transthoracic echocardiography (Cypress Acuson; Siemens
Medical Solutions, Malvern, Pa) with a 3.5-MHz probe was performed be-
fore infarction and then weekly in all animals. Parasternal long-axis images
were obtained by placing the ultrasound probe along the fourth through
seventh intercostal spaces with the animal in the upright, standing position.
Stroke volume was calculated as the difference in LV EDV and LV end-
systolic volume (ESV), and LV EF was calculated as the ratio of stroke vol-
ume to LV EDV.
CMR imaging. In part II, CMR imagingwas performed in all subjects
8 weeks after coronary ligation (but before restraint device implantation) to
confirm development of heart failure and then monthly after restraint de-
vice placement (Figure 1). Imaging was performedwith a 3-Tesla magnetic
resonance scanner (Signa CV/i; General Electric Healthcare, Milwaukee,
Wis). All acquisitions were obtained with an 8-element cardiac phased-
array surface coil with the animal in the lateral decubitus position under
general anesthesia and proper ventilation. Peripheral pulse gating and
breath holding were used as much as possible to minimize cardiac and re-
spiratory motion, respectively. Details of the CMR sequences and imaging
parameters have been published previously.8
Serum brain natriuretic peptide measurement. Relative
concentrations of serum brain natriuretic peptide (BNP) were determined
using a modified Dotblot technique. A 2-mL portion of each serum sample
was placed onto a 0.2-mm nitrocellulose membrane (catalog no. 162-0168;FIGURE 1. Representative cardiac magnetic resonance imaging short-
axis section (delayed enhancement series) of heart failure ovine subject. In-
farcted area is white and identified by upper arrow. The adjustable and
measurable ventricular restraint (AMVR) device is identified by lower ar-
rows and the fluid within the device can be clearly seen as black. The
AMVR device surrounds the entire heart but is only partially seen here ow-
ing to the cut of this particular image. LV, Left ventricle.
826 The Journal of Thoracic and Cardiovascular SurgBio-Rad Laboratories, Hercules, Calif). After drying, the membranes were
primed in 50 mL of a 5% bovine serum albumin (Sigma-Aldrich, St Louis,
Mo) in 1X phosphate-buffered saline (GIBCO/Invitrogen, Carlsbad, Calif)
followed by incubation in a 1:1000 solution of primary rabbit anti-BNP
polyclonal antibody (catalog no. BML BA1117; Bio-Mol Intl., Plymouth
Meeting, Pa). The membranes were washed in 1X phosphate-buffered
saline with 1% Tween followed by dark room incubation with a 1:3000
fluorescent secondary antibody solution (Alexa-Fluor 680 GoRRRat
Anti-Rabbit immunoglobulin G, catalog no. A21109; Invitrogen). Each
sample was analyzed for the intensity of the 700-nm infrared signal over
circular areas surrounding the dot at 3.5 intensity (Odyssey Imager; Li-
Cor Biosciences, Lincoln, Neb).
Myocardial matrix metalloproteinase-2 measurement.
At the end of the experimental period, all animals underwent terminal study
and explantation of the heart. The infarcted area was identified and the LV
bisected. Tissue samples were taken from 3 zones: infarct (identified by
whitish fibrotic discoloration), border (defined as tissue located between
the outer border of the infarct and 5 mm outward beyond that border),
and normal (remote, pink, and healthy appearing LV). All samples were
flash frozen in liquid nitrogen and stored at 80C. Myocardial matrix
metalloproteinase-2 (MMP-2) levels were analyzed using a Western blot
technique as described below.
Protein extraction and determination of total protein
concentration. Tissue samples were ground with a mortar and pestle,
suspended in 200 mL of lysis buffer (20 mmol/LTRIS-HCl–based Cell Ly-
sis Buffer, catalog no. 9803; Cell Signaling Technology, Danvers, Mass)
containing 1X phenylmethanesulfonylfluoride, and sonicated at 35% effi-
ciency. After centrifugation at 13,000 rpm for 20 minutes at 4C, the super-
natant was diluted 10:1. The protein concentration for each sample was
determined by incubating 25 mL of the diluted supernatant with 125 mL
of alkaline copper tartrate solution (Reagent A, catalog no. 500-0113;
Bio-Rad) and 1000 mL of dilute Folin reagent (Reagent B, catalog no.
500-0114; Bio-Rad). The absorbance of each sample at 595 nm was mea-
sured by spectrophotometry. The protein concentration (in micrograms per
milliliter) was determined by comparing these absorbance values to that of
a protein standard.
Protein electrophoresis and transfer. The calculated volume of
each sample containing 50 mg of total protein was added to 12 mL of 2X
loading buffer (Laemmly Sample Buffer, catalog no. 161-0737; Bio-
Rad), 2 mL of beta-mercaptoethanol (catalog no. 161-0710; Bio-Rad),
and cell lysis buffer and then incubated at 95C for 10minutes. Electropho-
resis was performed using 20 mL of each sample in precast gels (4%-12%
Criterion XT Bis-Tris precast polyacrylamide gel, catalog no. 345-0124;
Bio-Rad) with running buffer (Criterion XT MOPS Running Buffer, cata-
log no. 161-0788; Bio-Rad). Protein transfer onto a 0.45-mm pore size pol-
yvinylidene difluoride transfer membrane (Immobilon-P PVDF Transfer
Membrane, catalog no. IPVH08310; Millipore, Billerica, Mass) in TRIS/
glycine buffer (catalog no. 161-0771; Bio-Rad) was performed. Mem-
branes were then incubated with a 1:1000 rabbit anti-MMP-2 antibody so-
lution (gift from Dr William Stetler-Stevenson of the National Institutes of
Health/National Cancer Institute), followed by dark-room incubation with
a 1:3000 fluorescent secondary antibody solution (Alexa-Fluor 680 Goat
Anti-Rabbit immunoglobulin G, catalog no. A21109; Invitrogen). Each
band was analyzed at 3.5 intensity for the intensity of the 700-nm infrared
signal over the surrounding rectangular area.Statistics
All data are expressed as mean standard error. Mean values of param-
eters between groups were compared using a general linear mixed model.
Of the 144 data points collected, 8 (5.6%) were missing at random owing to
sporadic equipment malfunction or unavailability (such as the CMR mag-
net, imaging analysis software, or infrared scanner). These missing values
were imputed using the linear trend at point method. Repeated measuresery c March 2013
TABLE 1. LV volumes for all subjects in part I
LV EDV (mL) LV ESV (mL) LV EF (%)
Pre Post Mean D Pre Post Pre Post
Control 110 (13) 165* (6) þ52% (16) 82 (16) 115* (8) 26 (6) 23 (8)
Low restraint 129 (7) 106* (11) 18%y (4) 94 (13) 61* (10) 28 (5) 41* (9)
High restraint 133 (19) 95* (13) 28%y (2) 95 (12) 67* (16) 28 (3) 44* (9)
Left ventricular (LV) size and function changes with adjustable and measurable ventricular restraint. EDV, End-diastolic volume; ESV, end-systolic volume; EF, ejection fraction;
Pre, time point of adjustable and measurable ventricular restraint device implant; Post, after 2 months of therapy. *P<.05 for change within subjects from Pre to Post therapy.
yP<.05 for difference in percentage change from Pre to Post therapy between low and high restraint subjects.
Lee et al Evolving Technology/Basic Sciencedata were assessed using a repeated measures design to control for the in-
terrelatedness of our outcomes. Statistics were performed using SPSS 13.0
(SPSS, Inc, Chicago, Ill).
Anesthesia and Postoperative Care
For all operative procedures, we used standard perioperative and post-
operative methods previously described.7,8RESULTS
Part I: Long-Term Effects of Initial Restraint Level
Ventricular size and function. Ventricular volume data
are listed in Table 1. Figure 2 summarizes the effects of ini-
tial restraint level on LV size and function. In control sub-
jects in which no restraint was applied, the LV continued
to enlarge while EF declined. In both treatment groups,
LV EDVand ESV decreased and EF improved. The degree
of improvement in LV volumes correlated to the level of re-
straint therapy applied, with high restraint leading to greater
decreases in LV volume than low restraint. After 8 weeks of
treatment, LV EDV decreased by an average of 18.2% in
the low restraint group (P ¼ .005) and by 28.4% in the
high restraint group (P ¼ .012), whereas LV EF improved
from 28% to 41% in the low restraint group (P ¼ .012)
and from 28% to 44% in the high restraint group (P¼ .03).
Rate of reverse remodeling. Both restraint groups dis-
played reductions in LV EDV, with high restraint resultingFIGURE 2. Mean change in left ventricular end-diastolic volume (LV
EDV) after restraint device implantation for the low and high restraint
groups. *P<.05 for change in LV EDV from time zero (start of restraint
therapy).
The Journal of Thoracic and Cain a statistically significant decrease in LV EDV occurring
earlier than in low restraint (Figure 2). The rate of reverse
remodeling (ie, the rate of change in LV EDV per week)
was not constant for the 2 groups, as shown in Figure 3:
the rate peaked at 21 days for high restraint and at 35
days for low restraint. After these time points, reverse re-
modeling subsequently slowed in both groups.
Effect of reverse remodeling on measured restraint
level. As reverse remodeling occurred and LV EDV de-
creased, measured restraint level decreased in both restraint
groups. The high restraint group maintained the initial re-
straint level (ie, 3.0 mm Hg as set at the time of AMVR de-
vice implantation) longer than did the low restraint group:
in the high restraint group, the measured restraint level
did not begin to fall until LV EDV decreased by 13%,
whereas in the low restraint group, the measured restraint
level began to decrease after a 4% reduction in LV EDV.Part II: Optimized, Adjustable Restraint Versus
Standard, Nonadjustable Restraint
Ventricular size and function. Volume and hemodynamic
data results are listed in Table 2. LV volumes decreased and
LVEF increased in both treatment groups (Figure 4,A andB).FIGURE 3. Rate of reverse remodeling (change in left ventricular end-
diastolic volume [LV EDV] per week) for the low and high restraint groups
in part I.
rdiovascular Surgery c Volume 145, Number 3 827
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TABLE 2. LV volume data for subjects in part II
Standard restraint
(n ¼ 6)
Adjustable restraint
(n ¼ 6)
LV EDV (mL)
Pre 106 (11) 150 (31)
Post 99*,y (8) 130*,y (25)
LV ESV (mL)
Pre 70 (9) 102 (24)
Post 62*,y (8) 81*,y (17)
LV EDV indexed to body
weight (mL/kg)
Pre 2.1 (0.3) 3.4 (0.7)
Post 1.7*,y (0.3) 2.4*,y (0.7)
LV ESV indexed to body
weight (mL/kg)
Pre 1.3 (0.2) 2.3 (0.5)
Post 1.0*,y (0.2) 1.5*,y (0.4)
LV EF (%)
Pre 33.8 (3.2) 32.4 (3.1)
Post 38.4* (4.8) 38.3* (1.8)
Stroke volume (mL)
Pre 35 (4) 48 (9)
Post 38 (3) 50 (9)
Stroke volume indexed to
body weight (mL/kg)
Pre 0.7 (0.1) 1.0 (0.2)
Post 0.7 (0.1) 0.9 (0.3)
Cardiac output (L/min)
Pre 3.7 (1.2) 4.9 (1.3)
Post 4.2 (1.0) 5.4 (2.3)
Body weight (kg)
Pre 51 (7) 48 (5)
Post 57 (5) 55 (2)
Left ventricular (LV) size and function changes with adjustable and standard restraint.
EDV, End-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; Pre,
time point of restraint device implant; Post, after 2 months of therapy. *P<.05 for
change within treatment group from Pre to Post therapy. yP<.05 for difference in
change from Pre to Post therapy between standard and adjustable restraint groups.
FIGURE 4. Mean change in left ventricular end-diastolic volume (LV
EDV) (A) and left ventricular ejection fraction (LV EF) (B) after restraint
device implantation for the adjustable and standard restraint groups in
part II. *P<.05 for change in LV EDV from time zero (start of restraint
therapy).
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LV EDV decreased by 12.7% (P ¼ .005), LV ESV de-
creased by 19.0% (P< .001), and LV EF increased by
18.2% (P ¼ .014). In the standard restraint group, LV
EDV decreased by 5.7% (P ¼ .032), LV ESV decreased
by 9.4% (P ¼ .001), and LV EF increased by 13.6%
(P<.001). LV ventricular volumes were indexed to animal
body weight (LV EDV index and LV ESV index) to account
for any potential effects of animal growth during the study
period. These indexed volumes also decreased significantly
(P<.05) for both restraint groups. The difference in change
between the adjustable and standard restraint groups was
statistically significant for LV EDV (P ¼ .006), LV ESV
(P ¼ .001), LV EDV index (P ¼ .009), and LV ESV index
(P ¼ .003). RV EDV and RV EF showed no significant
change in either group throughout the study period: RV
EDV increased by 5% (P ¼ .1) and RV EF had no change
(P ¼ .87) in the adjustable group, whereas RV EDV828 The Journal of Thoracic and Cardiovascular Surgincreased by 1.2% (P ¼ .72) and RV EF increased by
1.6% (P ¼ .79) in the standard group.
Plasma BNP. Coronary artery ligation resulted in an aver-
age rise in plasma BNP of 37% by the eighth postoperative
week in all subjects. After restraint device placement,
plasma BNP levels subsequently fell in both groups
(Figure 5). By the end of the 2-month treatment period,
the plasma BNP level decreased by 12.6% (when compared
with the level at time of restraint device implantation) with
adjustable restraint (P¼ .47) and by 4.5%with standard re-
straint (P ¼ .64). There was no significant difference be-
tween the adjustable and standard groups (P ¼ .38).
Myocardial tissueMMP-2. In each subject, the infarct zone
had significantly higher levels of MMP-2 than either the bor-
der or normal zones (P ¼ .02). Among the different groups,
the control group displayed substantially higher levels of
MMP-2 in all tissue zones (infarct, border, and normal) than
both restraint groups (Figure 6). Between the restraint groups,ery c March 2013
FIGURE 5. Plasma brain natriuretic peptide (BNP) levels in the adjust-
able and standard restraint groups.
Lee et al Evolving Technology/Basic Sciencethe adjustable group had slightly lower levels of MMP-2, par-
ticularly in the border and infarct zones, than the standard
group, but this was not statistically significant (P ¼ .6).
DISCUSSION
Ventricular restraint therapy is a promising surgical op-
tion for heart failure. Studies using the Acorn CorCap Car-
diac Support Device (Acorn Cardiovascular, Inc) and the
Paracor Heartnet Device (Paracor Medical Systems, Sunny-
vale, Calif) have shown restraint to be one of the few ther-
apies that can reverse pathologic LV remodeling in both
animal models and patients.1-5,12,13
Further optimization of this therapy, however, will re-
quire a comprehensive understanding of the precise rela-
tionship between the restraint level applied and the
reverse remodeling engendered. By using our adjustable de-
vice in a sheep model, we7 previously demonstrated that re-
straint level has a direct effect on ventricular mechanicsFIGURE 6. Myocardial matrix metalloproteinase-2 (MMP-2) levels in
the normal, border, and infarct zones for the adjustable, standard, and con-
trol groups. MMP-2 levels are highest in the infarct zone for all subjects.
MMP-2 levels are significantly higher in the control group than either re-
straint treatment group. IR, Infrared.
The Journal of Thoracic and Ca
E
T
/B
Ssuch as LV transmyocardial pressure and indices of myocar-
dial oxygen consumption, with higher restraint levels lead-
ing to greater decreases in these parameters. Do such
changes in ventricular mechanical indices, however, trans-
late into similar changes in the amount of reverse remodel-
ing? No study has yet evaluated the relationship between the
amount of applied restraint and the degree of ventricular re-
modeling. We sought to address that question in this study.
The results from part I demonstrate that with fixed, non-
adjusted restraint, the initial restraint level significantly af-
fects both the degree and rate of reverse remodeling. Higher
restraint level leads to greater and earlier reductions in LV
EDV compared with the lower restraint level (Figure 2).
Why would higher restraint be more effective? So long as
tamponade is avoided, greater restraint leads to greater re-
ductions in LV transmyocardial pressure and indices of
myocardial oxygen consumption.7,8 This implies a greater
reduction in ventricular wall stress, which, by extension,
would cause greater reverse remodeling. Higher restraint
levels apply more pressure on the epicardium not only at
end-diastole but also through diastolic filling.7 We postulate
that this prolonged exposure to higher epicardial pressure
promotes increased cellular processes to induce earlier re-
verse remodeling. Such molecular alterations have been ob-
served in other situations where positive, nontamponade
epicardial pressure is applied, such as continuous positive
airway pressure therapy for sleep apnea.14
What happens to restraint level as the heart shrinks? Not
surprisingly, as reverse remodeling occurs and the LV de-
creases in size, there is a corresponding reduction in the
measured restraint level. Inasmuch as fluid is neither added
nor removed from the AMVR balloon, the shrinking heart
causes the restraint device to effectively loosen. As the ef-
fective restraint level decreases, this results in a diminishing
epicardial pressure driving the reverse remodeling process
forward and reverse remodeling itself slows. In other words,
reverse remodeling activity peaks and then declines with
concomitant peaks and declines in restraint level. This
may help explain clinical data findings in which reverse re-
modeling slows in patients after 3 months of therapy with
fixed, nonadjustable restraint wraps.11,12 We conclude that
the rate of reverse remodeling for an unchanging restraint
device is a function of both the initial restraint level and
therapy time. Indeed, the relationship between rate of
reverse remodeling and therapy time appears to be
nonconstant and nonlinear (Figure 3) and doubtless is a dy-
namic interaction between ventricular size, remodeling, and
measured restraint level.
On the basis of these findings, we hypothesized that peri-
odic adjustmentof the restraint device tomaintain a therapeu-
tic restraint level throughout treatment would be superior to
therapy applied in a standard, nonadjusted manner. We pos-
tulated that bymaintaining a desired restraint pressure (ie, by
intermittently adjusting the fluid volume within the AMVRrdiovascular Surgery c Volume 145, Number 3 829
Evolving Technology/Basic Science Lee et al
E
T
/B
Sdevice), therapy would be optimized by eliminating the re-
duction in restraint level caused by the progression of reverse
remodeling. This approach would hypothetically apply
a continuing impetus to drive forward reverse remodeling
even in the face of decreasing ventricular size.
This study demonstrates that adjustable restraint leads to
greater reverse remodeling than standard, nonadjustable re-
straint. LV EDV decreased by approximately 6%with stan-
dard restraint, consistent with results seen in clinical studies
of mesh-like restraint wraps.11 Adjustable restraint, how-
ever, led to a nearly twofold greater improvement with a re-
duction in LVEDVof approximately 13%. To assess for any
effect of animal growth during the treatment period, ventric-
ular volume data was indexed to body weight (which ranged
from 40 kg at the start of the study to 65 kg at the end of the
study). The adjustable group showed greater improvement
in these indexed values than did the standard restraint group
(P<.05). This suggests that as the heart undergoes reverse
remodeling and shrinks, serial measurement and adjustment
of the restraint device to maintain the optimal restraint level
leads to enhanced therapeutic benefit.
Does restraint therapy cause decreased LV EDV and LV
ESV at the expense of hemodynamic output? In this study,
cardiac output was not compromised with either adjustable
or standard restraint. Rather, cardiac output and stroke vol-
ume were increased in both groups at the end of the study
period, implying that the observed reduction in ventricular
volumes was not associated with hemodynamic decompen-
sation but rather indicative of a true beneficial reverse re-
modeling process. Possible adverse effects on coronary
blood flow can be a concern with excessive epicardial con-
striction. Large animal studies have shown that application
of a meshlike restraint device at levels of up to 2.5 mm Hg
can be safely applied without significant detrimental effects
on coronary blood flow.15 This corresponds with our current
and previous findings of beneficial changes with restraint up
to 3 mm Hg without adverse hemodynamic effects.
The degree of maximal improvement in LV EDV in part I
(28% in the high restraint group) was different from that
found in part II (13% in the adjustable group). We attribute
this difference to the different imaging modalities used:
transthoracic echocardiography and CMR. These imaging
techniques vary greatly in the methodology of measuring
and quantifying ventricular dimensions, which could ex-
plain the difference in observed maximal change in ventric-
ular volumes.
We observed changes in molecular markers of heart fail-
ure that further confirm the observedmorphologic and func-
tional changes. Serum BNP rose, as expected, with the
development of heart failure after coronary artery ligation.
BNP levels then fell with the initiation of restraint therapy.
There was no significant difference between the adjustable
and standard restraint groups. BNP measurements alone
may not be sufficient to use as a quantitative guide to titrate830 The Journal of Thoracic and Cardiovascular Surgtherapy but could play an adjunctive role in combination
with other monitoring parameters.
Myocardial tissue MMP plays a role in cardiac remodel-
ing after myocardial infarction, particularly in the region of
ischemia, and serum levels of MMP-2 have been correlated
with degree of heart failure.16-19 In our study, we found the
infarct zone had the highest levels of MMP-2 in all subjects
regardless of treatment status. MMP-2 levels were signifi-
cantly lower in the 2 treatment groups (adjustable restraint
and standard restraint) than in control subjects. Between the
2 restraint therapy groups, the adjustable group displayed
lower MMP-2 levels than the standard group, although
this difference was not statistically significant. Nonetheless,
our findings do suggest that restraint therapy in general
leads to less MMP-associated remodeling and provides
one possible mechanism by which restraint engenders re-
verse remodeling at the molecular level.
This study does have several limitations. In part I, there
were relatively small numbers of animals in each group.
Yet, despite the low subject numbers, the study was suffi-
ciently powered to demonstrate statistically significant re-
sults. The animal model used was a sheep model of LV
postinfarction heart failure and remodeling, and our data
should be interpreted with this in mind. Effects of ventric-
ular restraint therapy may be different in heart failure
caused by other etiologies or in right heart failure. Another
potential weakness that merits future investigation is the
duration of therapy. The current project was composed
of 4-month studies with treatment times of 2 months. Ad-
ditional studies must address issues such as the maximum
extent of reverse remodeling that is possible and whether
pathologic remodeling recurs after termination of restraint
therapy.
We used ventricular geometry and size as a marker for
ventricular reverse remodeling. This is an accepted tech-
nique used clinically for patients with heart failure. An im-
portant and useful adjunct, however, would have been
direct measurements of cardiac chamber pressures with
corresponding pressure–volume analyses. Our group7,8
has previously published acute pressure–volume analyses
in an identical ischemic heart failure model with the
AMVR device. Those studies served as the foundation for
the current study, and those data would strongly suggest
that had they been measured, the corresponding
hemodynamic measurements for this study would be
similarly improved.
Conceptually, ventricular restraint therapy is simply con-
trolled and beneficial cardiac constriction at pretamponade
levels where systemic hemodynamics are not adversely af-
fected. Restraint level should be titrated to enhance reverse
remodeling without creating tamponade. Within the param-
eters of this physiologic framework, this study shows that re-
straint level is intimately correlated with the subsequent
reverse remodeling. To maximize therapeutic efficacy,ery c March 2013
Lee et al Evolving Technology/Basic Scienceobjective criteria should be established regarding the precise
method of restraint application and adjustment for any indi-
vidual patient. Clinically tested restraint devices do not ade-
quately allow for this. Adjustable and measureable restraint
eliminates these shortcomings by potentiating therapy that is
more effective than and superior to standard restraint.
Our results demonstrate that by adjusting and measuring
restraint level both at the beginning of therapy and as the
heart shrinks during active reverse remodeling, restraint
therapy can be optimized for improved therapeutic reverse
remodeling. We submit that measurable and adjustable
ventricular restraint techniques, combined with hemody-
namic guides such as real-time echocardiography, could
ultimately determine the optimal restraint level for any
given individual at any treatment interval. As the heart re-
verse remodels and restraint level decreases, periodic ad-
justment of the restraint device would then optimize and
enhance subsequent reverse remodeling for improved ther-
apeutic efficacy.
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